publication date: Sep. 4, 2020

NCI Trials

NCI Trials for September 2020

The National Cancer Institute approved the following clinical research studies last month. 

For further information, contact the principal investigator listed.

 

Phase I/II – 10382

A Phase I/II Trial Evaluating the Safety and Efficacy of Eribulin in Combination with Copanlisib in Patients with Metastatic Triple Negative Breast Cancer

Yale University Cancer Center LAO

Bagegni, Nusayba

(314) 747-1171

 

Phase II – ANBL19P1

A Pilot Study of Dinutuximab, Sargramostim (GM-CSF), and Isotretinoin in Combination with Irinotecan and Temozolomide in the Post-Consolidation Setting for High-Risk Neuroblastoma

Children’s Oncology Group

Desai, Ami V.

773-834-3943

 

Phase II – EA6191

The BAMM2 (BRAF, Autophagy, MEK Inhibition in Melanoma) Study: A Randomized Double Blind Phase II Study of Dabrafenib and Trametinib with or Without Hydroxychloroquine in Advanced BRAF V600E/K Melanoma

ECOG-ACRIN Cancer Research Group

Amaravadi, Ravi

(215) 796-5159

 

Phase II/III – NRG-LU007

RAndomized Phase II/III Trial of Consolidation Radiation + Immunotherapy for ES-SCLC: RAPTOR Trial

NRG Oncology

Nguyen, Quynh-Nhu

(713) 563-2447

 

Phase III – A011801

The COMPASSHER2 Trials (COMprehensive Use of Pathologic Response ASSessment to Optimize Therapy in HER2-Positive Breast Cancer): COMPASSHER2 Residual Disease (RD), A Double-Blinded, Phase III Randomized Trial of T-DM1 Compared with T-DM1 and Tucatinib

Alliance for Clinical Trials in Oncology

O’Sullivan, Ciara C.

(507) 293-0526

 

Phase III – NRG-GU009

Parallel Phase III Randomized Trials for High Risk Prostate … Continue reading NCI Trials for September 2020

To access this members-only content, please log in.
Institutional subscribers, please log in with your IP.
If you're not a subscriber why not join today?
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2020 The Cancer Letter Inc.